Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes

NCT00160160 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2009-01-30

No results posted yet for this study

Summary

This study is to demonstrate the superiority of combination of eprosartan/HCTZ versus ramipril/HCTZ.

Conditions

Interventions

DRUG

eprosartan/HCTZ

Sponsors & Collaborators

  • Solvay Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Global Clinical Director Solvay · Solvay Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31

Countries

  • Canada
  • Denmark
  • France
  • Germany
  • Italy
  • Norway
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00160160 on ClinicalTrials.gov